EMEA-002515-PIP01-18 - paediatric investigation plan

human immunoglobulin G2 isotype antibody to IL-33R

Key facts

• Active substance:
  human immunoglobulin G2 isotype antibody to IL-33R
• Therapeutic area:
  Pneumology-allergology
• Decision number:
  P/0055/2020
• PIP number:
  EMEA-002515-PIP01-18
• Pharmaceutical form(s):
  Powder for solution for injection
• Condition(s) / indication(s):
  Treatment of asthma
• Route(s) of administration:
  Intravenous use
• Decision type:
  P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
• Decision date:
  10/02/2020
• Compliance check done:
  No

Decision

P/0055/2020: EMA decision of 10 February 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for human immunoglobulin G2 isotype antibody to IL-33R (EMEA-002515-PIP01-18)

Adopted Reference Number: EMA/26711/2020